Arcutis Biotherapeutics (ARQT) Treasury Shares (2019)

Arcutis Biotherapeutics' Treasury Shares history runs 7 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• In Q1 2026, Treasury Shares fell 14.75% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (down 14.75% YoY), while the FY2025 annual figure was $6.0 million, down 0.79% from the prior year.
• Treasury Shares for Q1 2026 stood at $6.1 million, up from $6.0 million in the prior quarter.
• The five-year high for Treasury Shares was $7.2 million in Q1 2025, with the low at $1.6 million in Q3 2022.
• The 5-year median for Treasury Shares is $6.1 million (2024), against an average of $4.9 million.
• The sharpest annual moves came in 2022 and 2026: Treasury Shares soared 370.33% in 2022, then slipped 14.75% in 2026.
• Arcutis Biotherapeutics' Treasury Shares stood at $1.6 million in 2022, then jumped by 85.83% to $2.9 million in 2023, then soared by 106.69% to $6.1 million in 2024, then retreated by 0.79% to $6.0 million in 2025, then climbed by 2.08% to $6.1 million in 2026.
• Business Quant data shows ARQT's Treasury Shares at $6.1 million in Q1 2026, $6.0 million in Q4 2025, and $6.2 million in Q3 2025.